AKT1 and primary central nervous system lymphoma: Various clinical trials have investigated the effects of small molecules targeting these pathways and immune checkpoint inhibitors, such as immunomodulatory imide drugs,28, 29 PI3K/AKT/mTOR inhibitors,22 and immune checkpoint inhibitors,21 for the treatment of CNS lymphoma.